Ask AI
ProCE Banner Activity

EMBRACE: 12 Mo Results With Lotivibart + LA CAB for People Living With Virologically Suppressed HIV

Conference Coverage
Slideset

In people with virologically suppressed HIV on stable ART, switching to the investigational bNAb lotivibart, administered every 4 months in combination with long-acting cabotegravir, maintained virologic suppression through 12 months in those with HIV susceptible to lotivibart at baseline.

Released: February 27, 2026

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

Supported by independent educational grants from Gilead Sciences, Inc., Merck & Co., Inc., Rahway, NJ, USA, and ViiV Healthcare.

Gilead Sciences, Inc.

Merck & Co., Inc., Rahway, NJ, USA

ViiV Healthcare

Target Audience

This activity is intended for physicians, pharmacists, registered nurses, and other healthcare professionals who care for people living with or at risk of HIV infection.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Appropriately apply and counsel patients regarding the clinical role(s) of new and investigational ART regimens and strategies

  • Devise HIV management strategies based on the results of recent clinical studies of established antiretroviral agents

  • Integrate the latest scientific findings to develop and optimize effective HIV prevention interventions